Launch of Dr Morepen LightLife in India
RNS & Investor News
Directorate Change
23 October 2024
OptiBiotix Health plc ("OptiBiotix") announces that Graham Myers, Finance Director of the Company, has notified the Company that he will step down from the Board on 30 November 2024.
David Blain will join the Company as acting Finance Director on 1 November 2024. Mr Blain's appointment to the Board of the Company will be subject to normal regulatory due diligence.
David is a member of ICAEW and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.
The Company notes recent speculation in relation to the health of the Company's Chief Executive Officer Stephen O'Hara. Mr O'Hara is recovering after a short illness and expects to be back at work shortly.
Neil Davidson, Chairman of OptiBiotix Health plc said: "On behalf of the Board, I would like to thank Graham for his contribution to the Company over the last year and welcome David as we move to our next stage of growth."
For further information, please contact: OptiBiotix Health plc | ||
Neil Davidson, Chairman | Contact via Walbrook below | |
Stephen O'Hara, Chief Executive | ||
| ||
Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
Liam Murray / Jo Turner / Ludovico Lazzaretti | ||
| ||
Peterhouse Capital Limited (Broker) | Tel: 020 7220 9797 | |
Duncan Vasey / Lucy Williams | ||
Walbrook PR Ltd | Mob: 07876 741 001 | |
Anna Dunphy |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Latest RNS News
Latest Video
ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023
www.proactiveinvestors.co.uk
Latest Podcast
Stephen OHara interview with Investors Champion
Stephen O'Hara | 04 Jul 2019
www.investorschampion.com